The Regulatory Due Diligence Specialist: Reading Someone Else's Submission History Before a Deal Closes

Introduction

When a biotech licenses a compound to a larger partner, or a strategic buyer moves to acquire a company for its pipeline, the deal does not close on the strength of a pitch deck. Somewhere in the weeks before signature, a regulatory professional sits down with the target's entire submission history and asks a narrower, harder question than the one the bankers are asking: does this asset's regulatory file actually support the story the deal is being priced on? That work has a name, even if it rarely appears on an organizational chart as its own job title. It is regulatory due diligence, and it has quietly become one of the more interesting assignments a regulatory affairs professional can pick up mid-career.

This is not a full-time role at most companies. It is usually a project a senior regulatory affairs manager, director, or outside consultant takes on in addition to their regular work, activated whenever business development needs a regulatory read on a target. But the skill set is distinct enough, and the stakes high enough, that it is worth understanding on its own terms: what the review actually covers, who tends to get asked to do it, and how the output differs from the day-to-day regulatory work most people recognize.

What Triggers a Regulatory Due Diligence Review

Regulatory due diligence shows up wherever money is about to change hands based on the value of a regulated asset: an acquisition, an in-license or out-license deal, a co-development agreement, or sometimes a later-stage financing round where investors want independent confirmation that a program's regulatory status is what the company says it is. The triggering event is always the same shape, even when the deal structure differs: someone outside the asset's home team needs to verify, on a compressed timeline and usually under a non-disclosure agreement, that the regulatory record is as clean, as advanced, or as de-risked as the valuation assumes.

The request typically comes from business development or corporate development, not from a regulatory counterpart at the target. A due diligence specialist is often working with limited access, a data room full of PDFs, and a deadline measured in days rather than weeks. That constraint shapes everything about how the work gets done.

Reading the Submission File Like a Detective

The core of the job is forensic reading. A due diligence reviewer works through the target's correspondence with health authorities and reconstructs the real narrative behind the filing, which is often different from the summary the business team has been given. That means pulling apart the sequence of meeting minutes, information requests, and responses to look for patterns: Has the agency raised the same concern more than once without full resolution? Does a complete response letter's underlying issue actually get addressed in the resubmission, or just acknowledged? Were there protocol deviations or data integrity findings in a trial that never surfaced in the company's own slide deck?

Reviewers also look hard at designation status, since it changes both the regulatory pathway and the commercial math. Breakthrough therapy, fast track, orphan drug, or priority review designations are frequently cited in deal materials as settled facts, but the review needs to confirm the designation is still active, matches the indication actually being pursued, and was granted on the trial population the buyer intends to rely on. A designation granted for a narrower population than the one in the deal thesis is a common and expensive gap to miss.

CMC and Manufacturing Risk

Clinical data gets the most attention in a deal narrative, but chemistry, manufacturing, and controls risk is where due diligence specialists often find the most consequential surprises. A due diligence review looks at whether the manufacturing process described in the regulatory file is the same one the target actually plans to use at commercial scale, whether a planned technology transfer to a new site or contract manufacturer has been discussed with the agency, and whether comparability data exists to support any process changes made along the way. An asset that looks clinically de-risked can still carry significant regulatory risk if a site transfer or scale-up has not been pressure-tested against what the health authority has already seen.

This is also where due diligence work overlaps most directly with quality and manufacturing colleagues. A thorough review pulls in input on inspection history, warning letters, and the state of any open corrective actions, because an acquirer inheriting a facility inherits its compliance history along with it.

Who Does This Work and How They Get the Assignment

Most people doing regulatory due diligence are not junior. The work requires enough pattern recognition across multiple therapeutic areas and submission types to spot what is missing from a data room, not just what is present in it, and that judgment tends to come with years of hands-on filing experience. Senior regulatory affairs managers and directors who have personally run submissions through agency review, including at least one difficult cycle involving a complete response letter or a major information request, are the most common internal candidates.

Consultants and boutique regulatory advisory firms do a substantial share of this work, particularly for smaller biotechs and venture funds that do not have in-house regulatory leadership senior enough to run the review independently. Being known within a therapeutic area network as someone with sound judgment under time pressure is often how these assignments arrive, more than any formal application process. People who want this kind of work tend to find it finds them, once colleagues and former managers know they can be trusted with a compressed, confidential review.

The Deliverable: Risk Memos, Not Just Checklists

The written output of a due diligence review looks different from most regulatory deliverables. Rather than a submission-ready document, the end product is usually a risk memo written for a non-regulatory audience: the deal team, finance, and sometimes the board. It needs to translate technical findings into business consequences, stated plainly enough that someone without a regulatory background can use them to adjust a valuation model or walk away from a term.

A well-written memo does not just flag problems. It ranks them by how much they would change the deal's timeline or value, distinguishes a fixable procedural gap from a structural one, and is explicit about what could not be verified given the access the reviewer had. That last point matters more than it might seem. Due diligence is almost always conducted with incomplete information, and a reviewer who pretends otherwise does the deal team a disservice.

Skills That Make Someone Good at This

Beyond deep submission experience, the people who do this work well share a few traits. They read quickly without skimming, which is a harder combination than it sounds when working through hundreds of pages of correspondence on a tight deadline. They are comfortable stating a professional opinion with appropriate caveats rather than hedging into uselessness, because a deal team needs a clear read, not a list of open questions. And they can work alongside legal, finance, and quality counterparts without territorial friction, since due diligence is inherently a team sport under time pressure.

Confidentiality discipline is non-negotiable. Reviewers routinely see material, non-public information about companies they may later compete against, negotiate with, or even work for, and the professional reputation of anyone doing this work rests on handling that information correctly every time.

How to Position Yourself for Due Diligence Work

There is no credential that certifies someone for regulatory due diligence, and that is unlikely to change. The realistic path is building a track record of filing experience across a reasonable range of submission types, developing a reputation for sound judgment, and being visible enough within a therapeutic area or regulatory affairs network that colleagues think to ask. Volunteering for an internal licensing evaluation, even a small one, is one of the few ways to get a first rep at this kind of work before an outside firm or a corporate development team comes calling directly.

What Happens After the Deal Closes

A due diligence memo does not end a regulatory professional's involvement in a deal, even though the assignment itself is usually framed as a one-time review. The findings in that memo typically become the basis for a post-close integration plan: which open agency commitments need to be picked up immediately, which manufacturing comparability studies still need to be run, and which designation renewals or annual report filings are coming due on a calendar the acquiring company did not set. A due diligence specialist who stays engaged through this handoff, even briefly, tends to deliver more value than one who disappears once the memo is submitted, because the gap between what a deal team understood on signing day and what the integration team actually needs to execute is often where regulatory risk resurfaces.

This is also where due diligence work can quietly become a pipeline into a new role. It is common enough for a reviewer who impressed a deal team with a clear, well-caveated assessment to be asked to lead the regulatory integration workstream once the transaction closes, or to be offered a permanent position overseeing the acquired asset going forward. Treating a due diligence assignment as disposable, one-off work undersells what it can lead to.

Common Mistakes in Due Diligence Reviews

A few recurring mistakes separate a mediocre due diligence review from a genuinely useful one. The first is treating the assignment as a document inventory rather than an analysis: simply confirming that an IND or marketing application exists and was accepted, without digging into whether the underlying correspondence shows unresolved concerns. The second is failing to flag the limits of the review clearly enough, since a data room with gaps is the norm rather than the exception, and a memo that reads as more confident than the access actually supported can lead a deal team to underprice real risk.

A third common mistake is working in isolation from quality, manufacturing, and legal counterparts, producing a technically accurate regulatory assessment that nonetheless misses an inspection finding or a contractual obligation that changes the picture. The best due diligence work treats the review as inherently cross-functional from the first day, not something to be handed off at the end for other teams to reconcile against their own findings.

Conclusion

Regulatory due diligence rewards exactly the kind of judgment that years of running real submissions builds: knowing what a clean file actually looks like, recognizing the shape of a problem before it is labeled as one, and being able to say so clearly to people who are not regulatory professionals themselves. It is not a job title most people set out to pursue, but for regulatory affairs professionals who have put in the time on the filing side, it is one of the more consequential ways that experience gets reused.